Skip to main content
. 2020 May 11;130(6):3098–3112. doi: 10.1172/JCI130546

Figure 4. Targeting the S100A8/A9 pathway limits susceptibility to chronic TB and TB reactivation.

Figure 4

Mtb-infected B6 and S100A9KO (n = 10) mice were treated with RAGE inhibitor (1 mg/kg RAGE-specific blocker FPS-ZM1 [n = 5] or DMSO in PBS [n = 5]) at 205 dpi for 15 days, and (A) lung bacterial burden at 220 dpi was determined by plating. (B) Pulmonary inflammation was quantified on FFPE lung sections stained with H&E, and (C) area occupied by B cell follicles was quantified histologically. B6 (n = 9) or S100A9KO (n = 13) infected mice were treated with rifabutin (100 mg/l) and INH (200 mg/l) for 6 weeks, and mouse organs were then harvested and homogenized at 140 dpi to determine reactivation of Mtb infection. (D) Lung bacterial burden was determined by plating, (E) pulmonary inflammation was quantified on FFPE lung sections stained with H&E, and (F) quantification of MPO+Ly6G+ neutrophils was carried out in FFPE lung sections. Figures depict 1 experiment representative of 2 or combined data from multiple experiments. Data points represent the mean ± SEM of values. (A) One-way ANOVA with Tukey’s posttest; (B–F) Student’s t test between groups. *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001.